A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared with Budesonide pMDI 80 μg - CHASE 3

Inclusion Criteria

• Inclusion Criteria:
• - Has a documented clinical diagnosis of asthma defined by the ATS for at least 6 months prior to Visit 2
• - Have a morning pre-bronchodilator clinic FEV1 measured at least 6 hours after the last dose of inhaled SABA and at least 48 hours after last dose of inhaled LABA of 60% to 100% of predicted normal
• - Demonstrated reversibility of clinic FEV1 of ≥12% from pre –albuterol/salbutamol level within 15 to 30 minutes after administration of a standard dose of albuterol/salbutamol.
• Exclusion Criteria:
• -Have been hospitalized at least once or required emergency treatment more than once for an asthma-related condition during the 6 months prior to Visit 1
• -Have required treatment with systemic corticosteroids (eg, oral, parenteral, or rectal) for any reason within the 6 weeks prior to Visit 1